Clinical Trials Directory

Trials / Completed

CompletedNCT05640895

Intravitreal Injection Site and Perceived Pain

The Effect of Entry Site Distance From Limbus on Perceived Pain During Intravitreal Injection of Anti-VEGF (Vascular Endothelial Growth Factor) Agents

Status
Completed
Phase
Study type
Observational
Enrollment
53 (actual)
Sponsor
The University of Texas Medical Branch, Galveston · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Accepted

Summary

The objective of this study is to explore the perception of pain during intravitreal injection related to the distance of the entry site from the limbus.

Detailed description

In this pilot cross-over study, the investigators aim at exploring a factor not studied yet on the perception of pain during the injection procedure, and that is the distance of the entry site from the limbus. Study population: Pseudophakic patients needing multiple intravitreal injections. In case of bilateral eligibility, one eye per patient will be included (randomly- based on a random chart). Intervention: two injections per eye, will be included in the study. All steps of the technique will be similar between the two injections except for the entry site distance from the limbus, which will be 3.5 in one and 4.00 mm in the other. To prevent bias, the first injection entry distance will be randomly selected (based on a randomized chart). The patient is blind to the entry distance, and a questionnaire with a visual analog pain scale will be given to the patient by a technician (to prevent any bias) to be filled after the injection. The analog pain scale is a scale of numbers from 0 to 10 representing the degree of patient's perceived pain. A score of 0 indicates no perception of pain; a score of 10 indicates a perception of the worst pain possible. The scale is also illustrated with face emojis corresponding to a written description of pain perception from no perception of pain, represented by a green, fully smiling face to perception of the worst pain possible, represented by a red, crying, fully frowning face.

Conditions

Interventions

TypeNameDescription
PROCEDUREIntravitreal injection siteIntravitreal injections will be made at varying sites; patients will report on pain perception

Timeline

Start date
2022-11-14
Primary completion
2023-12-18
Completion
2024-09-09
First posted
2022-12-07
Last updated
2025-01-31

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05640895. Inclusion in this directory is not an endorsement.